Joachim Widder

CCC Vienna and Chair, Dept of Radiation Oncology

[EORTC @EORTC]

We are excited to share that we reached 100 patients enrolled in the #ReCare cohort of #E2RADIatE.

More info: https://t.co/GjrtqZEUsb

@ESTRO_RT @WBA_Global @jonas_willmann @widder_joachim @NAndratschke #ClinicalTrials

[Joachim Widder @widder_joachim]

https://t.co/0PvIVS3HwK

Opinion:
* keep indications for metastases-directed local therapy (MDT) and the biology of OMD conceptually apart
* serial clinical imaging is key
* declare failure of MDT only at progression to polymetastatic disease if unamenable to re-MDT

[Matthias Guckenberger @Mat_Guc]

Virtual symposium by @EORTC and @ESTRO_RT #OligoCare consortium

🔥 Hot topics and challenges in SBRT for oligometastatic disease 🔥

Do not miss these 🥇 speakers
@drdavidpalma
@_ShankarSiva
@GiulioFrancoli1
@piet_ost
and many more !

Registration 👇
https://t.co/LyDT8lU5tq

[Joachim Widder @widder_joachim]

NRG LU002 closed after phase II and will not go on to phase III. Seemingly same situation and same reason as NRG BR002: PFS again was primary endpoint, and PFS still is not a suitable primary endpoint for trials comparing MDT vs systemic only therapy. (https://t.co/T7Wg707NPt)

[Puneeth Iyengar @IyengarPuneeth]

I would like to thank all the patients, investigators, institutions, protocol team members, @NRGonc, @NCICancerTrials, and many others who helped with NRG LU002. We made incredible history in successfully randomizing to the largest OMD NSCLC trial to date evaluating local therapy

[Comprehensive Cancer Center Vienna (CCC) @CCCVienna]

@cancerCCR @Pathologie_MUW @MedUni_Wien @drpolterauer @gojojohannes @l_wadiura @WalterBerger19 @EckertFranziska @Uro_MedUniWien @widder_joachim @ElmarJoura @RichardCrevenna @EvaSchernhammer @ChristineOnco

[Kurt Langbein @KurtLangbein]

Sie haben dementiert, gelöscht, geschreddert. Aber das #projektballhausplatz" liess sich rekonstruieren - hier der Trailer. Ab 21. September im Kino

[VCÖ @VCOE_AT]

Ein autofreies Stadtviertel für 12.000 Menschen - keine Utopie, sondern in #Utrecht ab 2024 Realität. #Klimaschutz #Verkehrswende

[EORTC @EORTC]

We are delighted to announce that the first site for #ReCare, a cohort of the #E2RADIatE platform, has been activated.

More: https://t.co/rFtnk9wBif

@WBA_Global, @NAndratschke, @jonas_willmann, Nieder Carsten, #CancerResearch #ClinicalTrials #Oncology

[Joachim Widder @widder_joachim]

@Mat_Guc Thanks! NY times meanwhile even removed the highly inappropriate word from the title of a not well balanced report on the study

[Matthias Guckenberger @Mat_Guc]

"On behalf of the European radiation oncology community and our patients, ESTRO urges a return to responsible communication presenting scientific facts in a balanced manner with headlines that inform rather than alarm."

[ASTRO @ASTRO_org]

ASTRO statement is https://t.co/rLSb19yyEu

[Jeff Michalski @jmmrad]

Overall this is an advance for the management of patients with rectal cancer but patients need to be carefully selected, closely monitored, and informed of the trade offs between the toxicity profiles of various treatment options. @ASCO @ESTRO_RT @Mat_Guc

[ASTRO @ASTRO_org]

The American Society for Radiation Oncology (ASTRO) Gastrointestinal Cancers Resource Panel issued the following statement regarding the PROSPECT clinical trial for patients with rectal cancer: https://t.co/rLSb19y0OW

[Richard Sullivan @SullivanProf]

The abysmal state of global research funding on key domains such as surgery, radiotherapy and health services. Combined less than 4%. How have research funding organisations managed to get their strategic priorities so wrong? ⁦@cspramesh⁩ ⁦ https://t.co/QahAfMjsK1

[Matthias Guckenberger @Mat_Guc]

Double-blinded phase III RCT: RT vs sham-RT for painful Morbus Ledderhose (n=84 pts)
Sig. benefit of RT
👉 1a mean pain score 2.5 vs 3.6 (p=0.03)
👉 1a pain relief 74% vs 56% (p=0.002)
👉 improved QoL & walking speed
👉 mild RT tox
👏 first RCT
#radonc
https://t.co/hPUoXBlfmd

[Filippo Alongi @alongi_filippo]

Honored to present @ESTRO_RT the results of the @EORTC E2-RADIatE #oligocare international cohort analysis including 1468 patients treated with #SBRT in #oligomet. See you in Vienna. https://t.co/CI70ve8ii3

[Joachim Widder @widder_joachim]

@ArminWolf @vpetritsch In NL war das Tempolimit 2016 nicht 100, sondern 120. Die Verkehrsdicht ist dort x mal höher als in AUT.

[Drew Moghanaki @DrewMoghanaki]

⚡️Alerting @Docace911 and @IyengarPuneeth before its too late: https://t.co/N8xhElX43W

[Joachim Widder @widder_joachim]

@MedUni_Wien @JCO_ASCO Gyn Unit CCC Vienna/Rad.Onc.
MR-IGABT: New emerging standard in treatment for cure of locally advanced cervical cancer.
N=1318
LC: 95% SCC, 86%
OS > 80% at 5y

[MedUni Wien @MedUni_Wien]

Researchers from #MedUniVienna and #UniversityHospitalVienna have demonstrated the superiority of a targeted approach to #brachytherapy. The results provide a basis for customised treament for patients with advanced #cervicalcancer. ➡️ https://t.co/O5Nd7thXJe

@jco_asco